Comparison of dexmedetomidine to propofol for sedation of endobronchial ultrasound-guided transbronchial needle aspiration
Background: Dexmedetomidine, a sedative agents viaα2 adrenergic agonist, provides light sleep-like sedation with little respiratory suppression. The study aims to evaluate the efficacy and safety of dexmedetomidine sedation compared with propofol in endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).
Method: Patients requiring elective EBUS-TBNA were randomized into: Dexmedetomidine (D, n=10), dexmedetomidine 1ug/kg infusion for 10 minutes and 0.5~1.4ug/kg/hour or propofol (P, n=15), the effect-site concentration targeted to 2.0ug/ml ±0.2ug/ml to achieve stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3~2. Vital signs and bispectral index (BIS) during bronchoscopy and recovery time were recorded. Patients' tolerance, awareness and cooperation during bronchoscopy were evaluated by 100 mm-visual analog scale (VAS, 0: no bother; 100: the worst intolerance).
Results: The lowest mean arterial blood pressure in D was higher than P (83.0±9.2 vs. 71.4±15.3mmHg, p=0.03). The lowest heart rate was significant lower in D than P (58.9±9.4 vs. 70.9±12.4 beat/min, p=0.03). The mean BIS during sedation was significant higher in D than P (p<0.001). Oxygenation, recovery time, tolerance and awareness were similar in both groups. The cooperation is better in D compared to D (p=0.01).
Conclusion: Dexmedetomidine provided a lighter sedation, reduced heart rate without compromised blood pressure and tolerance of patients undergoing EBUS-TBNA compared to propofol. Dexmedetomidine sedation provided better patient cooperation for of EBUS-TBNA.
Publisher URL: http://erj.ersjournals.com/cgi/content/short/54/suppl_63/PA320
DOI: 10.1183/13993003.congress-2019.PA320
Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.
Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.